# Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

> **NCT05509361** · PHASE3 · COMPLETED · sponsor: **Akeso** · enrollment: 950 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** AK101 injection SC

## Key facts

- **NCT ID:** NCT05509361
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 950 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509361, "Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05509361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*